Senseonics (NYSE:SENS) announced today that Anthem is providing coverage for implantable continuous glucose monitoring (CGM).
The coverage extends to the Eversense CGM system — including the recently launched next-generation Eversense E3 180-day CGM — meaning that Senseonics’ global commercial partner, Ascensia Diabetes Care, can introduce the CGM to more people living with diabetes.
Germantown, Maryland-based Senseonics received FDA approval in February for use lasting up to six months (180 days), making it the longest-lasting CGM sensor available in the U.S. Eversense E3 features a third-generation sensor with SBA technology that enhances sensor longevity to make it what the company says is the longest-lasting CGM system. The sensor is fully implantable and requires just two sensor insertion and removal procedures per year.
According to a news release, the decision from Anthem (now Elevance Health), the second-largest health insurance company in the U.S., will add more than 45 million covered lives for the long-term implantable CGM system for helping to manage diabetes. Senseonics said it adds to the “growing number of payers who are writing Eversense into their CGM coverage policies that now benefit approximately 250 million covered lives, as well as paying for the healthcare provider’s time for the in-office sensor insertion.”
Cigna, Aetna, Humana, HCSC Blue Cross Blue Shield and others have committed to broad-based coverage across the U.S. from the majority of commercial payers, the company said.
“Anthem is dedicated to delivering better care to its members and improving the health of the communities it serves. We are excited for Anthem members to have the ability to effectively manage their diabetes through the only long-term implantable CGM system available,” Senseonics President and CEO Tim Goodnow said in the news release. “Eversense provides patients with actionable glucose data, enabling users to proactively manage their glucose levels.
“With its six-month sensor life, sustained accuracy, on-body vibratory alerts and remote monitoring capability, Eversense E3 offers patients an advanced CGM to help effectively manage their diabetes and experience healthier outcomes.”